سعر نوفونورم 2مجم 30 قرص 2025

NovoNorm 2 mg tablets, pack of 30 (Novo Nordisk; distributed in Egypt by Egyptian Pharmaceutical Trading Company): repaglinide, a short-acting prandial insulin secretagogue for type 2 diabetes.

• Adults with type 2 diabetes mellitus whose hyperglycaemia is no longer satisfactorily controlled by diet, weight reduction and exercise; also in combination with metformin when metformin alone is insufficient. Started as an adjunct to diet and exercise to lower meal-related blood glucose.Population: AdultsEuropean Medicines Agency (EMA)
• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; not for type 1 diabetes or diabetic ketoacidosis.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Hypoglycaemia is the most frequent reaction (common); also common abdominal pain and diarrhoea. Rare cardiovascular disease; very rare allergic reactions, refraction disorders, vomiting, constipation and abnormal hepatic function/increased liver enzymes; hypersensitivity skin reactions and nausea frequency not known.International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to repaglinide or any excipient; C-peptide-negative type 1 diabetes; diabetic ketoacidosis with or without coma; severe hepatic function disorder; concomitant gemfibrozil.International label, same product · European Medicines Agency (EMA)
• Concomitant use of gemfibrozil; known hypersensitivity to repaglinide or any inactive ingredient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Can cause hypoglycaemia like other insulin secretagogues; combination with metformin increases hypoglycaemia risk. Stress (fever, trauma, infection, surgery) may cause loss of glycaemic control requiring temporary insulin.International label, same product · European Medicines Agency (EMA)
• Use might be associated with an increased incidence of acute coronary syndrome (e.g. myocardial infarction). Benefit-risk of combination with NPH insulin or thiazolidinediones remains to be established.International label, same product · European Medicines Agency (EMA)
• Not indicated in combination with NPH insulin: serious myocardial ischemia events were reported with repaglinide plus NPH insulin.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• GemfibrozilIncreased repaglinide AUC 8.1-fold and prolonged half-life; concomitant use is contraindicated.European Medicines Agency (EMA)
• ClopidogrelIncreased repaglinide exposure 5.1-fold (loading dose) and 3.9-fold (75 mg daily); avoid; if necessary monitor blood glucose closely.European Medicines Agency (EMA)
• Ciclosporin, deferasirox, trimethoprimIncrease repaglinide exposure (about 2.5-, 2.3- and 1.6-fold respectively); avoid concomitant use, or monitor glucose and clinical status closely if necessary.European Medicines Agency (EMA)

• There are no studies of repaglinide in pregnant women; repaglinide should be avoided during pregnancy.International label, same product · European Medicines Agency (EMA)
• Limited data from case reports and case series have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; poorly controlled diabetes in pregnancy carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• There are no studies in breast-feeding women; repaglinide should not be used in breast-feeding women.International label, same product · European Medicines Agency (EMA)

• Repaglinide: Closes ATP-dependent potassium channels in pancreatic beta-cell membranes via a distinct target protein, depolarising the cell and opening calcium channels; the calcium influx stimulates insulin secretion (EU NovoNorm SmPC 5.1).